Aurinia Submits IND Application to US Food & Drug Administra

AUR200, a potent recombinant fusion protein, has a clinically validated MOA with a high affinity for targeting both BAFF and APRIL



Upon FDA clearance of the IND, AUR 200 will be studied in a...

Related Keywords

Maryland , United States , Rockville , Volker Knappertz , Research Development , Nasdaq , Drug Administration , American College Of Rheumatology Convergence , Aurinia Pharmaceuticals , Aurinia Pharmaceuticals Inc , Investigational New Drug , B Cell Activating Factor , Proliferation Inducing Ligand , Executive Vice President , American College , Rheumatology Convergence , Increased Potency , Accessed December , Markets ,